Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.

Overview of attention for article published in Journal of Clinical Oncology, January 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 3 news outlets
reddit: 1 Redditor

bluesky: 1 Bluesky user

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

More Is Not Always Better: Innovations in Oncology Treatment and Diagnostics

AJMC, 14 Apr 2025

Oncology has seen waves of innovation in diagnostics, treatment, and patient management in recent years.

Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC

OncLive, 26 Jan 2025

CRC | © Sebastian Kaulitzki – stock.adobe.com The use of a tumor-informed, personalized circulating tumor DNA (ctDNA) assay…

ctDNA Shows High Recurrence Detection Sensitivity in Stage II/III CRC

Cancer Network, 26 Jan 2025

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.